Hisense Bio Stock

Hisense Bio offers treatment for intractable dental diseases using physiological and periodontal ligament regeneration technology.

Sign up today and learn more about Hisense Bio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Hisense Bio Stock

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

Funding History

March 2018$2.0B
May 2019$7.0B
May 2021$13.0B

Management

CEO

Park Joo-cheol

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo